Learn more about Edwards SAPIEN Transcatheter Aortic Heart Valve
In November of 2011, the U.S. Food and Drug Administration (FDA) approved the Edwards SAPIEN Transcatheter Heart Valve for the treatment of patients with severe
symptomatic native aortic valve stenosis who have been determined by a cardiac surgeon to be inoperable for open aortic valve replacement, and in whom existing
co-morbidities would not preclude the expected benefit from correction of the aortic stenosis.
